MedPath

Effects of Polynucleotides and Hyaluronic Acid Based Subgingival Periodontal Pockets Re-instrumentation

Not Applicable
Completed
Conditions
Periodontal Pocket
Interventions
Other: subgingival re-instrumentation
Registration Number
NCT05210686
Lead Sponsor
University of Roma La Sapienza
Brief Summary

The purpose of this randomized controlled clinical trial (RCT) was to investigate the clinical and biochemical efficacy of a gel containing PDRN and HA used in association with subgingival re-instrumentation in the treatment of residual periodontal pockets.

Detailed Description

The aim of the present study was to investigate the clinical and biochemical efficacy of a gel containing polynucleotides (PDRN) and hyaluronic acid (HA) used in association with subgingival re-instrumentation in the treatment of residual periodontal pockets.

50 patients were enrolled in a randomized, split-mouth clinical trial. For each patient, two teeth with similar residual pockets with probing depth (PD) ≥ 5 mm were selected to receive re-instrumentation with (test) or without (control) the adjunctive use of a PDRN and HA based gel. Differences in changes of PD, gingival recession (REC), clinical attachment level (CAL), modified sulcular bleeding index (mSBI), plaque index (PLI) from baseline to 6, 8, 24, 36 and 48 weeks were analyzed and the frequencies of sites with PD \<4 mm at 48 weeks were compared. Furthermore, changes in the dosage of alpha-2-macroglobulin (α2M) and of matrix metalloproteinase-9 (MMP-9) from baseline to 6 weeks were evaluated.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
50
Inclusion Criteria
  • males and females with ≥ 18 years
  • stage 3 generalized periodontitis
  • 3-6 months after step 1 and 2 of periodontal treatment, at least two non-adjacent teeth showing one residual pocket with probing depth (PD) ≥5, without mobility and without furcation involvement.
Exclusion Criteria
  • full-mouth plaque score (FMPS) and full-mouth bleeding score (FMBS) >20%
  • inadequate restorative therapy or malocclusion
  • uncontrolled systemic disease
  • immunosuppressive therapy or therapy with corticosteroid or with bisphosphonates
  • inflammatory and autoimmune diseases of the oral cavity
  • history of malignancy, radiation therapy or chemotherapy for malignancy in the last 5 years
  • insulin-dependent diabetes;
  • smoking (> 10 cigarettes per day)
  • drug and alcohol abuse
  • pregnant or lactating.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
subgingival re-instrumentation + gel containing PDRN and HAsubgingival re-instrumentationsubgingival re-instrumentation + gel containing PDRN and HA
subgingival re-instrumentationsubgingival re-instrumentationsubgingival re-instrumentation
Primary Outcome Measures
NameTimeMethod
Pocket depth12 months

Clinical evaluations were performed by a blind calibrated examiner, different from the investigator who performed the treatment. At baseline (visit 1) and at 6 (visit 2), 8(visit 3), 24 (visit 4), 36 (visit 5) and 48 (visit 6) weeks using a periodontal probe

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Department of Oral and Maxillofacial Sciences. Section of Periodontics.Sapienza, University of Rome

🇮🇹

Rome, Italy

© Copyright 2025. All Rights Reserved by MedPath